Acrivon Therapeutics, Inc. Common Stock
ACRVAcrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company's platform combines genomics, proteomics, and machine learning to identify targeted therapies and biomarkers, aiming to improve patient outcomes in various oncology indications.
Company News
A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.
Acrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.
Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.
AstraZeneca's lung cancer drug Tagrisso has been approved by the European Commission for use in combination with chemotherapy as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer. The approval was based on positive data from the FLAURA2 study, which showed Tagrisso plus chemotherapy reduced the risk of disease progressio...
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.
